1. Design and Pharmacodynamics of Recombinant Fungus Defensin NZL with Improved Activity against Staphylococcus hyicus In Vitro and In Vivo.
- Author
-
Liu, He, Yang, Na, Teng, Da, Mao, Ruoyu, Hao, Ya, Ma, Xuanxuan, and Wang, Jianhua
- Subjects
- *
CEFTRIAXONE , *LABORATORY mice , *STAPHYLOCOCCUS , *DEFENSINS , *ANTIMICROBIAL peptides , *PHARMACODYNAMICS , *SWINE industry , *PICHIA pastoris - Abstract
Staphylococcus hyicus is recognized as a leading pathogen of exudative epidermitis in modern swine industry. Antimicrobial peptides are attractive candidates for development as potential therapeutics to combat the serious threats of the resistance of S. hyicus. In this study, a series of derivatives were designed based on the NZ2114 template with the aim of obtaining peptides with more potent antimicrobial activity through changing net positive charge or hydrophobicity. Among them, a variant designated as NZL was highly expressed in Pichia pastoris (P. pastoris) with total secreted protein of 1505 mg/L in a 5-L fermenter and exhibited enhanced antimicrobial activity relative to parent peptide NZ2114. Additionally, NZL could kill over 99% of S. hyicus NCTC10350 in vitro within 8 h and in Hacat cells. The results of membrane permeabilization assay, morphological observations, peptide localization assay showed that NZL had potent activity against S. hyicus, which maybe kill S. hyicus through action on the cell wall. NZL also showed an effective therapy in a mouse peritonitis model caused by S. hyicus, superior to NZ2114 or ceftriaxone. Overall, these findings can contribute to explore a novel potential candidate against S. hyicus infections. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF